Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 108, Issue 12, Pages djw154
Publisher
Oxford University Press (OUP)
Online
2016-07-06
DOI
10.1093/jnci/djw154
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database
- (2015) Qian Shi et al. JOURNAL OF CLINICAL ONCOLOGY
- Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival
- (2015) Satoshi Morita et al. JNCI-Journal of the National Cancer Institute
- Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival
- (2015) Satoshi Morita et al. JNCI-Journal of the National Cancer Institute
- frailtypack: AnRPackage for the Analysis of Correlated Survival Data with Frailty Models Using Penalized Likelihood Estimation or Parametrical Estimation
- (2015) Virginie Rondeau et al. Journal of Statistical Software
- Rethinking Composite End Points in Clinical Trials
- (2014) Joshua M. Stolker et al. CIRCULATION
- Bayesian semiparametric analysis of semicompeting risks data: investigating hospital readmission after a pancreatic cancer diagnosis
- (2014) Kyu Ha Lee et al. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- A joint test for progression and survival with interval-censored data from a cancer clinical trial
- (2014) Dianne M. Finkelstein et al. STATISTICS IN MEDICINE
- Identification and estimation of survivor average causal effects
- (2014) Eric J. Tchetgen Tchetgen STATISTICS IN MEDICINE
- Use of composite endpoints in clinical trials
- (2014) Abdul J. Sankoh et al. STATISTICS IN MEDICINE
- Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching
- (2013) Yuanye Zhang et al. LIFETIME DATA ANALYSIS
- Progression-Free Survival: Meaningful or Simply Measurable?
- (2012) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- Statistical considerations when using a composite endpoint for comparing treatment groups
- (2012) Guadalupe Gómez et al. STATISTICS IN MEDICINE
- Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study
- (2011) D. Zeng et al. BIOMETRIKA
- Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
- (2011) Eitan Amir et al. EUROPEAN JOURNAL OF CANCER
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- The value of progression-free survival to patients with advanced-stage cancer
- (2011) Lesley J. Fallowfield et al. Nature Reviews Clinical Oncology
- Bayesian inference for an illness-death model for stroke with cognition as a latent time-dependent risk factor
- (2011) Ardo van den Hout et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Frailties in multi-state models: Are they identifiable? Do we need them?
- (2011) Hein Putter et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field
- (2010) Linda Wittkop et al. Clinical Trials
- Pitfalls of Using Composite Primary End Points in the Presence of Competing Risks
- (2010) Loren K. Mell et al. JOURNAL OF CLINICAL ONCOLOGY
- A semi-competing risks model for data with interval-censoring and informative observation: An application to the MRC cognitive function and ageing study
- (2010) Jessica K. Barrett et al. STATISTICS IN MEDICINE
- Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
- (2009) E. D. Saad et al. ANNALS OF ONCOLOGY
- Statistical Analysis of Illness-Death Processes and Semicompeting Risks Data
- (2009) Jinfeng Xu et al. BIOMETRICS
- Issues in Using Progression-Free Survival When Evaluating Oncology Products
- (2009) Thomas R. Fleming et al. JOURNAL OF CLINICAL ONCOLOGY
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial
- (2009) R. M. Goldberg et al. ONCOLOGIST
- Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues
- (2008) Aloka Chakravarty et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Multi-state models for the analysis of time-to-event data
- (2008) Luís Meira-Machado et al. STATISTICAL METHODS IN MEDICAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More